{"id":579351,"date":"2026-08-01T20:47:11","date_gmt":"2026-08-01T20:47:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/579351\/"},"modified":"2026-08-01T20:47:11","modified_gmt":"2026-08-01T20:47:11","slug":"e2-radiate-shows-how-prospective-registries-can-strengthen-radiation-oncology-research","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/579351\/","title":{"rendered":"E2-RADIatE Shows How Prospective Registries Can Strengthen Radiation Oncology Research"},"content":{"rendered":"

Radiotherapy<\/a> is a cornerstone of cancer care, but radiation oncology research still represents only a small part of the global oncology research portfolio.<\/p>\n

A new article published in Radiotherapy and Oncology highlights how prospective registries and real-world data can help close this evidence gap.<\/p>\n

The paper reports five years of experience from E2-RADIatE, the EORTC-ESTRO Radiotherapy Infrastructure for Europe, a collaborative project launched in 2019 by the European Organisation for Research and Treatment of Cancer and the European Society for Radiotherapy and Oncology.<\/p>\n

The platform was created to collect prospective real-world data on cancer patients, radiotherapy treatments, and outcomes across Europe.<\/p>\n

Why This Project Matters<\/p>\n

Radiotherapy continues to evolve rapidly.<\/p>\n

New technologies, treatment techniques, clinical indications, combinations with systemic therapies, and workflow innovations are constantly entering practice.<\/p>\n

However, generating evidence for radiotherapy innovations is often difficult.<\/p>\n

Randomized controlled trials remain essential, but they are not always easy to conduct in radiation oncology. Many radiotherapy advances are incremental, depend on technology and operator experience, require long-term endpoints, and often involve high upfront costs for hospitals.<\/p>\n

As a result, radiotherapy research accounts for only a small fraction of oncology research activity.<\/p>\n

This creates a need for complementary approaches to evidence generation, including prospective registries, real-world cohorts, pragmatic trials, and trial designs embedded in routine care.<\/p>\n

E2-RADIatE was built to address this need.<\/p>\n

What Is E2-RADIatE?<\/p>\n

E2-RADIatE is a pragmatic, observational, prospective multi-cohort platform.<\/p>\n

It collects real-world data from patients treated with radiotherapy across Europe through a centralized database.<\/p>\n

The platform is designed to be disease- and technology-agnostic, meaning it can support different radiotherapy questions, indications, and treatment approaches.<\/p>\n

It captures clinical outcomes, radiotherapy planning and delivery data, imaging information, patient-reported outcomes, patient experiences, resource use, and economic data.<\/p>\n

This makes it broader than many traditional oncology trials, which often focus mainly on survival, progression, or toxicity.<\/p>\n

The EORTC and ESTRO Partnership<\/p>\n

The project brings together the strengths of EORTC and ESTRO.<\/p>\n

EORTC provides long-standing clinical trial infrastructure and expertise in multicenter oncology research.<\/p>\n

ESTRO brings the radiation oncology community, professional networks, education, and strategic focus on equitable access to high-quality radiotherapy.<\/p>\n

Together, the two organizations created a pan-European framework to support radiotherapy-specific research questions and build evidence from daily clinical practice.<\/p>\n

Five Years of Progress<\/p>\n

After five years, two active cohorts are recruiting patients within E2-RADIatE.<\/p>\n

The first is OligoCare, which focuses on metastasis-directed radiotherapy for oligometastatic disease.<\/p>\n

The second is ReCare, which focuses on re-irradiation, an increasingly common but under-studied clinical situation.<\/p>\n

Together, these cohorts show how prospective real-world registries can capture complex radiotherapy practice across different countries, tumor types, treatment sites, technologies, and clinical scenarios.<\/p>\n

The platform has also supported scientific outputs, consensus recommendations, new hypotheses, and innovative trial methodology.<\/p>\n

OligoCare and Oligometastatic Disease<\/p>\n

OligoCare is the first and most mature E2-RADIatE cohort.<\/p>\n

It evaluates radical metastasis-directed radiotherapy in patients with oligometastatic disease from breast, non-small cell lung, prostate, or colorectal cancer.<\/p>\n

The cohort includes patients treated with local ablative intent, with at least one lesion treated using stereotactic body radiotherapy.<\/p>\n

By November 2025, OligoCare had enrolled 3,768 patients across 67 centers in 13 European countries.<\/p>\n

Early analyses have already provided important insights into real-world SBRT practice.<\/p>\n

One analysis of the first 1,004 patients showed that prostate cancer was the most common primary tumor, followed by non-small cell lung cancer, colorectal cancer, and breast cancer.<\/p>\n

The most frequently treated sites were non-vertebral bone, lung, and distant lymph node metastases.<\/p>\n

Most patients were treated for a single metastasis, and SBRT was usually delivered using multiple fractions.<\/p>\n

Early Safety and Quality-of-Life Data<\/p>\n

OligoCare has also generated early outcome data.<\/p>\n

In an interim analysis of 1,468 patients, acute grade 3 or higher SBRT-related adverse events within six months were rare, occurring in 0.5% of patients.<\/p>\n

Fatal events were reported in 0.1%.<\/p>\n

These findings support the short-term safety of metastasis-directed SBRT in routine European practice.<\/p>\n

Another analysis focused on health-related quality of life in men with oligometastatic prostate cancer.<\/p>\n

Most patients had good baseline global health status, and overall quality of life remained largely stable during the first six months after SBRT.<\/p>\n

These findings are important because metastasis-directed treatment should not only aim for tumor control, but also preserve patient well-being.<\/p>\n

ReCare and the Evidence Gap in Re-Irradiation<\/p>\n

ReCare focuses on high-dose re-irradiation.<\/p>\n

This is a growing area in radiation oncology, but prospective evidence remains limited.<\/p>\n

Clinicians often face difficult questions about cumulative dose, organ-at-risk tolerance, fractionation, retreatment safety, integration with systemic therapy, and patient selection.<\/p>\n

ReCare aims to collect high-quality data on tumor control, toxicity, imaging, radiotherapy plans, and quality-of-life outcomes.<\/p>\n

Launched in 2023, ReCare had enrolled 653 patients from 19 centers across 9 countries by November 2025.<\/p>\n

The first interim analysis included 290 patients with 348 lesions.<\/p>\n

Most re-irradiations occurred in the thorax and pelvis, with prostate, lung, and breast cancers among the most common primary tumors.<\/p>\n

More than 80% of cases involved overlap between the first and second radiotherapy volumes, and treatment intent was curative in more than two-thirds of patients.<\/p>\n

These early data confirm both the feasibility of large-scale re-irradiation data collection and the heterogeneity of current clinical practice.<\/p>\n

From Registry Data to New Trials<\/p>\n

A major strength of E2-RADIatE is that it does not only describe current practice.<\/p>\n

It also generates new hypotheses for future trials.<\/p>\n

One example is SPRINT, a trial embedded within the OligoCare cohort.<\/p>\n

OligoCare showed that more than 90% of SBRT treatments in Europe are delivered using multiple fractions. This raised the question of whether single-fraction SBRT could be a safe and efficient alternative for selected patients.<\/p>\n

SPRINT uses a Trial Within Cohorts design, known as TwiCs, to compare single-fraction SBRT with multi-fraction SBRT.<\/p>\n

This is the first international oncology TwiCs trial run through the platform.<\/p>\n

The design allows randomization to be embedded within an ongoing real-world cohort, reducing patient burden and improving external validity compared with many traditional trial designs.<\/p>\n

ALPHA-Care and Combining SBRT With Novel Drugs<\/p>\n

Another planned cohort is ALPHA-Care.<\/p>\n

This cohort will address a major practical question in oncology: how to safely combine SBRT with newly approved systemic therapies.<\/p>\n

In daily practice, clinicians often pause systemic treatment during SBRT because of toxicity concerns, while others may reduce radiotherapy intensity or avoid treatment.<\/p>\n

Both approaches may affect patient outcomes.<\/p>\n

ALPHA-Care is designed to generate early safety data on combinations of SBRT with novel anti-cancer drugs in patients with metastatic disease.<\/p>\n

This could help guide multidisciplinary decision-making and inform future efficacy trials.<\/p>\n

Key Lessons From E2-RADIatE<\/p>\n

The five-year experience shows that a prospective pan-European radiotherapy registry is feasible.<\/p>\n

It also shows that such platforms require strong community engagement, standardized data collection, quality assurance, sustainable funding, and clear governance.<\/p>\n

E2-RADIatE has already supported multiple abstracts, publications, consensus statements, and methodological innovations.<\/p>\n

It has also highlighted important challenges.<\/p>\n

These include funding limitations, hidden workload for participating centers, differences in ethics and data-protection requirements across countries, difficulty collecting complex DICOM radiotherapy data, and the need to harmonize registry infrastructure across Europe.<\/p>\n

Why Real-World Evidence Matters in Radiation Oncology<\/p>\n

Real-world evidence cannot replace randomized trials, but it can complement them.<\/p>\n

This is especially important in radiation oncology, where clinical practice is technically complex, rapidly evolving, and highly dependent on treatment delivery, imaging, planning, and local expertise.<\/p>\n

Prospective registries can help capture what happens in routine care, evaluate patterns of practice, identify variation, support benchmarking, generate hypotheses, and inform future trial design.<\/p>\n

They can also provide evidence for settings that are difficult to study through traditional randomized trials alone, such as oligometastatic disease, re-irradiation, rare subgroups, or technology-driven innovations.<\/p>\n

Clinical Takeaway<\/p>\n

The first five years of E2-RADIatE show that prospective real-world registries can become powerful research infrastructure for radiation oncology.<\/p>\n

Through OligoCare and ReCare, the platform is already helping describe European radiotherapy practice, evaluate safety and quality-of-life outcomes, develop consensus guidance, and generate new trial questions.<\/p>\n

Its experience also highlights what is needed for success: sustainable funding, standardized data structures, community engagement, regulatory harmonization, and integration of patient-centered outcomes.<\/p>\n

E2-RADIatE demonstrates that radiation oncology can learn systematically from routine care.<\/p>\n

For a field where innovation often moves faster than traditional evidence generation, this kind of infrastructure may become essential for building stronger, more relevant, and more patient-centered evidence.<\/p>\n

Read full article<\/a> here<\/p>\n","protected":false},"excerpt":{"rendered":"Radiotherapy is a cornerstone of cancer care, but radiation oncology research still represents only a small part of…\n","protected":false},"author":2,"featured_media":579352,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[61,60,80],"class_list":["post-579351","post","type-post","status-publish","format-standard","has-post-thumbnail","category-technology","tag-ie","tag-ireland","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/579351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=579351"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/579351\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/579352"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=579351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=579351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=579351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}